Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048292 · ClinicalTrials.gov registry record
New York City Mobile Interventional Stroke Team
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 191
- Enrollment target
NCT03048292 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 191 participants.
The verdict
NCT03048292 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 191 participants
- Enrollment target
Study Summary
Endovascular treatment has recently become the recommended therapy for acute stroke after the publication of five randomized trials (MR CLEAN1, ESCAPE2, EXTEND IA3, SWIFT PRIME4, REVASCAT5) in 2015 that demonstrate its efficacy. Hospitals need to adapt to these updated stroke care guidelines, and many hospitals are not appropriately equipped for neurointerventional procedures. Decreased time to treatment is associated with favorable clinical outcomes, and best practices to optimize workflow between comprehensive stroke centers and secondary hospitals have become an important area of study. This prospective study is being conducted on acute stroke cases within the Mount Sinai Health System from 1 June 2016 up until 31 December 2018. The researchers would like to evaluate how variable methods of interventional service delivery for acute stroke affect clinical measures and outcomes. More specifically, the researchers are conducting this study in order to determine whether outcomes of neurointervention for large vessel occlusion in stroke, for patients presenting to and receiving treatment at a comprehensive stroke center, will be superior to that delivered by a mobilized intervention team at a central satellite hospital. In particular, the hypothesis is that factors affecting outcome include presentation to secondary hospital, delays with transfer including traffic conditions and time of day, and the acquisition of complex imaging within secondary hospitals.
Interventions
- OTHER Acute Endovascular Stroke Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-07-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03048292
The ClinicalTrials.gov registry entry for NCT03048292 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acute Endovascular Stroke Treatment is the first listed.
NCT03048292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03048292 about?
NCT03048292 is a clinical study titled "New York City Mobile Interventional Stroke Team". Endovascular treatment has recently become the recommended therapy for acute stroke after the publication of five randomized trials (MR CLEAN1, ESCAPE2, EXTEND IA3, SWIFT PRIME4, REVASCAT5) in 2015 that demonstrate its efficacy. Hospitals need to adapt to these updated stroke care guidelines, and ma...
What is the current status of trial NCT03048292?
This trial is currently completed. The enrollment target is 191 participants. The study started on 2016-06. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT03048292?
The interventions under investigation include: Acute Endovascular Stroke Treatment (OTHER).
Who is sponsoring clinical trial NCT03048292?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.